Alkermes Announces the Appointment of Emily Peterson Alva to its Board of Directors
DUBLIN, May 20, 2021 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Emily Peterson Alva, to the company s Board of Directors ( Board ). Emily Peterson Alva is an experienced public company board member and a financial, strategic and business advisor to growth companies. A former Lazard M&A Partner with more than 15 years of investment banking experience, Ms. Alva brings significant experience navigating complex strategic, transactional and governance matters for public companies across many sectors including specific expertise in healthcare and pharmaceuticals. I am delighted to welcome Emily to Alkermes Board of Directors and look forward to her insights and perspectives as we focus our efforts on high return-on-investment opportunities that are consistent with our long-term growth strategy, said Richard Pops, Chief Executive Officer and
Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
Reflecting Rigorous Expense Management, Expected Revenue Growth and Commitment to Shareholder Value Creation -
- Announces Potential Monetization of Non-Core Assets and Reiterates Commitment to Exploring Strategic Collaborations Around ALKS 4230 -
- Two New Independent Directors Appointed and Board Refreshment Program to Continue -
- Alkermes to Host Investor Day in the First Quarter of 2021 to Update Investors on Plan Implementation and R&D Portfolio -
DUBLIN, Dec. 10, 2020 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced a Value Enhancement Plan, or the Plan, designed to drive growth, improve operational and financial performance and enhance shareholder value, as the company continues to advance its mission of developing new medicines designed to have a real-world impact in the treatment of serious mental illness, addiction and cancer. The Plan includes a commitment to multi-year pro